Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Major

fosphenytoin edoxaban

Applies to: fosphenytoin, edoxaban

MONITOR CLOSELY: Coadministration with inducers of P-glycoprotein (P-gp) may reduce the bioavailability of edoxaban, which is a substrate of the efflux transporter. According to the product labeling, the potent P-gp inducer rifampin decreased single-dose edoxaban systemic exposure (AUC) by approximately 35%.

MANAGEMENT: Caution is advised if edoxaban is used with P-gp inducers. Pharmacologic response to edoxaban should be monitored more closely whenever a P-gp inducer is added to or withdrawn from therapy, and the edoxaban dosage adjusted as necessary.

References (2)
  1. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  2. (2015) "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.